Axsome Therapeutics (AXSM) Could Be 25% Undervalued As CNS Pipeline Hopes Build
Axsome Therapeutics event context and recent stock performance
Axsome Therapeutics (AXSM) continues to draw investor attention as it advances therapies for central nervous system disorders, including approved treatments for depression, excessive daytime sleepiness, and migraine, alongside multiple late stage clinical programs.
The stock last closed at US$212.74 on 7 August 2026. Over the past month the share price declined 9%, while the past 3 months show a smaller fall of 1.7%, leaving the year to date return at 19.1%.
See our latest analysis for Axsome Therapeutics.
For Axsome Therapeutics, recent share price weakness over the past month contrasts with a much stronger longer term picture, with the 1 year total shareholder return above 100% and the 5 year total shareholder return above 8x. This suggests the latest moves likely reflect shifting expectations around future growth and risk rather than a simple break in the broader trend.
If Axsome Therapeutics has put CNS treatments on your radar, it may be a good time to see what else is moving in healthcare AI and related therapies through the 43 healthcare AI stocks
Bulls point to Axsome Therapeutics’ expanding CNS portfolio and recent revenue and net income growth. Bears focus on ongoing losses and a sharp run up in the stock. Which side does the current valuation actually support?
Most Popular Narrative: 24.7% Undervalued
Axsome Therapeutics' most followed narrative pegs fair value at about $282.51, compared with the recent close at $212.74. That gap rests on ambitious growth forecasts and a pipeline driven CNS portfolio.
The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.
Want to see what is behind that premium outlook for Axsome Therapeutics? The narrative leans heavily on rapid revenue expansion, margin improvement, and a richer earnings multiple than the wider pharmaceuticals sector. Curious how those pieces fit together into a single fair value number?
Behind the scenes, the most popular narrative assumes Axsome Therapeutics can compound revenue at a brisk pace, lift profit margins sharply from current losses, and sustain a higher future P/E than the broader US pharmaceuticals group, all discounted back using a 7.11% rate to reach that $282.51 figure.
Result: Fair Value of $282.51 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Axsome Therapeutics still faces real execution risk around Auvelity and Sunosi concentration, as well as ongoing net losses that could pressure liquidity and future dilution.
Find out about the key risks to this Axsome Therapeutics narrative.
Next Steps
With the optimism around Axsome Therapeutics front of mind, it helps to move quickly and test those assumptions against the numbers yourself. To see what investors are finding encouraging right now, start with the 3 key rewards.
Looking for more Axsome Therapeutics style investment ideas?
If Axsome Therapeutics has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that could reshape how you think about opportunity and risk.
- Scan for potential value opportunities that couple quality with attractive pricing through the 52 high quality undervalued stocks.
- Strengthen your income focus by reviewing companies that feature resilient cash flows and higher yields using the 8 dividend fortresses.
- Prioritise resilience by checking companies that show robust financial footing and fundamentals through the solid balance sheet and fundamentals stocks screener (48 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com